Obesity and Thromboembolic Disease

Clinics in Chest Medicine

Volumn 30, Issue 3, 2009, Pages 489-493

  Stein, Paul D ^a,b   Goldman, Jose ^c  

^a ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Deep venous thrombosis; Obesity; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

BARIATRIC SURGERY; BLOOD CLOTTING DISORDER; DEEP VEIN THROMBOSIS; EVIDENCE BASED MEDICINE; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; MORBID OBESITY; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

HEMOSTASIS; HUMANS; OBESITY; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 68849112614     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.05.006     Document Type: Review

References (51)

1. Giuntini C., Di Ricco G., Marini C., et al. Pulmonary embolism: epidemiology. Chest 107 1 Suppl (1995) 3S-9S
2. Anderson F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 (2003) I9-I16
3. Goldhaber S.Z., Savage D.D., Garrison R.J., et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 74 (1983) 1023-1028
4. Goldhaber S.Z., Grodstein F., Stampfer M.J., et al. A prospective study of risk factors for pulmonary embolism in women. J Am Med Assoc 277 (1997) 642-645
5. Stein P.D., Beemath A., and Olson R.E. Obesity as a risk factor in venous thromboembolism. Am J Med 118 (2005) 978-980
6. Nordstrom M., and Lindblad B. Autopsy-verified venous thromboembolism within a defined urban population-the city of Malmo, Sweden. Acta Pathol Microbiol Immunol Scand 106 (1998) 378-384
7. Stein P.D. Pulmonary embolism. 2nd edition (2007), Blackwell Futura, Oxford (UK) p. 3-18
8. Smith G.T., Dammin G.J., and Dexter L. Postmortem arteriographic studies of the human lung in pulmonary embolization. J Am Med Assoc 188 (1964) 143-151
9. Stein P.D., Kayali F., and Olson R.E. Regional differences in rates of diagnosis and mortality of pulmonary thromboembolism. Am J Cardiol 93 (2004) 1194-1197
10. Stein P.D., Beemath A., and Olson R.E. Trends in the incidence of pulmonary embolism and deep venous thrombosis in hospitalized patients. Am J Cardiol 95 (2005) 1525-1526
11. Stein P.D., Hull R.D., Patel K.C., et al. Venous thromboembolic disease: comparison of the diagnostic process in men and women. Arch Intern Med 163 (2003) 1689-1694
12. Stein P.D., Hull R.D., Patel K.C., et al. Venous thromboembolic disease: comparison of the diagnostic process in blacks and whites. Arch Intern Med 163 (2003) 1843-1848
13. Stein P.D., Kayali F., Olson R.E., et al. Pulmonary thromboembolism in Asian-Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 116 (2004) 435-442
14. Stein P.D., Kayali F., Olson R.E., et al. Pulmonary thromboembolism in American Indians and Alaskan Natives. Arch Intern Med 164 (2004) 1804-1806
15. Stein P.D., Hull R.D., Ghali W.A., et al. Tracking the uptake of evidence: two decades of hospital practice trends for diagnosing deep vein thrombosis and pulmonary embolism. Arch Intern Med 163 (2003) 1213-1219
16. Horlander K.T., Mannino D.M., and Leeper K.V. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163 (2003) 1711-1717
17. Stein P.D., Kayali F., and Olson R.E. Estimated case fatality rate from pulmonary embolism, 1979-1998. Am J Cardiol 93 (2004) 1197-1199
18. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 151 (1991) 933-938
19. Carson J.L., Kelley M.A., Duff A., et al. The clinical course of pulmonary embolism. N Engl J Med 326 (1992) 1240-1245
20. Stein P.D., and Henry J.W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 108 (1995) 978-981
21. Pannaciulli N., De Mitrio V., Marino R., et al. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 10 (2002) 717-725
22. Juhan-Vague I., Alessi M.C., Mavri A., et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1 (2003) 1575-1579
23. De Pergola G., and Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25 (2002) 899-904
24. Goichot B., Grunebaum L., Desprez D., et al. Circulating procoagulant microparticles in obesity. Diabete Metab 32 (2006) 82-85
25. VanWijk M.J., VanBavel E., Sturk A., et al. Microparticles in cardiovascular diseases. Cardiovasc Res 59 (2003) 277-287
26. Margaglione M., Cappuci G., d'Addedda M., et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 18 (1998) 562-567
27. Dusserre E., Moulin P., and Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 1500 (2000) 88-96
28. Alessi M.C., Peiretti F., Morange P., et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46 (1997) 860-867
29. Kohler H.P., and Grant P.J. Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
30. Levi M., Biemond B.J., van Zonneveld, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 85 (1992) 305-312
31. Zoccali C., Mallamaci F., and Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end stage renal disease. Kidney Int 84 Suppl (2003) S65-S68
32. Lindeman J.H., Pijl H., Toet K., et al. Human visceral adipose tissue and the plasminogen activator inhibitor type 1. Int J Obes (Lond) 31 (2007) 1671-1679
33. Basili S., Pacini G., Guagnano M.T., et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48 (2006) 2531-2538
34. Mertens I., and Van Gaal L.F. Obesity, haemostasis and the fibrinolytic system. Obes Rev 3 (2002) 85-101
35. Bara L., Nicaud V., Tiret L., et al. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring-the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost 71 (1994) 434-440
36. Duncan B.B., Schmidt M.I., Chambless L.E., et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults-the ARIC Study. Obes Res 8 (2000) 279-286
37. Snell A.M. The relation of obesity to fatal postoperative pulmonary embolism. Arch Surg 15 (1927) 237-244
38. Heit J.A., Silverstein M.D., Mohr D.N., et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 86 (2001) 452-463
39. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 152 (1992) 1660-1664
40. Hedley A.A., Ogden C.L., Johnson C.L., et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. J Am Med Assoc 291 (2004) 2847-2850
41. Abdollahi M., Cushman M., and Rosendaal F.R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 89 (2003) 493-498
42. Coon W.W., and Coller F.A. Some epidemiologic considerations of thromboembolism. Surg Gynecol Obstet 109 (1959) 487-501
43. Hansson P.O., Eriksson H., Welin L., et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the Study of Men Born in 1913.". Arch Intern Med 159 (1999) 1886-1890
44. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160 (2000) 3415-3420
45. US Department of Health and Human Services, Public Health Service, National Center for Health Statistics National Hospital Discharge Survey 1979-1999 multi-year public-use data file documentation. Available at:. http://www.cdc.gov/nchs/about/major/hdasd/nhds.htm Accessed March 21, 2009
46. Farmer R.D., Lawrenson R.A., Todd J.C., et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49 (2000) 580-590
47. Pomp E.R., le Cessie S., Rosendaal F.R., et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 139 (2007) 289-296
48. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65 (2002) 187-196
49. Nightingale A.L., Lawrenson R.A., Simpson E.L., et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 5 (2000) 265-274
50. Eichinger S., Hron G., Bialonczyk C., et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 168 (2008) 1678-1683
51. Hamad G.G., and Choban P.S. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the Prophylaxis Against VTE Outcomes in Bariatric Surgery Patients Receiving Enoxaparin (PROBE) study. Obes Surg 15 (2005) 1368-1374